Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q1

3341.TEDINET S100OZY9
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥74.7bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥299.4bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥71.9bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥892m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥936m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥913m2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥6.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥993m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥925m2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥993m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥391m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥427m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥391m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥427m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥195.3bnat 2022-06-30Cons.Assets
Total assets¥178.8bnat 2022-03-31Cons.Assets
Total assets¥199.1bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥142.4bnat 2022-06-30Cons.Liabilities
Total liabilities¥125.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥52.9bnat 2022-06-30Cons.Net assets
Net assets / equity¥52.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥49.9bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥31.5bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥25.5bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥13.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥123.562021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥14.272021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio27.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio25.1%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥1.8bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥355m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥6.3bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥270m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥78.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥74.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥2.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥1.7bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥62.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥62.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥278m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥12.2bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥7.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥451m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥77.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥71.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 352
ItemContextValueUnit
Number of shares held in own name treasury shares etcCurrentQuarterInstant2061100
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant2061100
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0643
Cash and depositsPrior1YearInstant25543000000JPY
Cash and depositsCurrentQuarterInstant31490000000JPY
Notes receivable tradePrior1YearInstant27000000JPY
Notes receivable tradeCurrentQuarterInstant68000000JPY
Trade receivables and contract asset caPrior1YearInstant20458000000JPY
Trade receivables and contract asset caCurrentQuarterInstant18950000000JPY
Electronically recorded monetary claims operating caPrior1YearInstant422000000JPY
Electronically recorded monetary claims operating caCurrentQuarterInstant468000000JPY
Merchandise and finished goodsPrior1YearInstant23024000000JPY
Merchandise and finished goodsCurrentQuarterInstant31979000000JPY
Work in processPrior1YearInstant1799000000JPY
Work in processCurrentQuarterInstant1909000000JPY
Raw materials and suppliesPrior1YearInstant6262000000JPY
Raw materials and suppliesCurrentQuarterInstant5970000000JPY
Other caPrior1YearInstant4121000000JPY
Other caCurrentQuarterInstant3866000000JPY
Allowance for doubtful accounts caPrior1YearInstant-8000000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-7000000JPY
Current assetsPrior1YearInstant81651000000JPY
Current assetsCurrentQuarterInstant94695000000JPY
Buildings and structures netPrior1YearInstant29559000000JPY
Buildings and structures netCurrentQuarterInstant29873000000JPY
LandPrior1YearInstant14155000000JPY
LandCurrentQuarterInstant14025000000JPY
Construction in progressPrior1YearInstant1226000000JPY
Construction in progressCurrentQuarterInstant1067000000JPY
Other net ppePrior1YearInstant19083000000JPY
Other net ppeCurrentQuarterInstant18958000000JPY
Property plant and equipmentPrior1YearInstant64025000000JPY
Property plant and equipmentCurrentQuarterInstant63925000000JPY
GoodwillPrior1YearInstant15220000000JPY
GoodwillCurrentQuarterInstant16332000000JPY
Other iaPrior1YearInstant3749000000JPY
Other iaCurrentQuarterInstant3953000000JPY
Intangible assetsPrior1YearInstant18969000000JPY
Intangible assetsCurrentQuarterInstant20285000000JPY
Investment securitiesPrior1YearInstant16000000JPY
Investment securitiesCurrentQuarterInstant16000000JPY
Lease and guarantee depositsPrior1YearInstant8797000000JPY
Lease and guarantee depositsCurrentQuarterInstant9070000000JPY
Other ioaPrior1YearInstant5293000000JPY
Other ioaCurrentQuarterInstant7346000000JPY
Investments and other assetsPrior1YearInstant14107000000JPY
Investments and other assetsCurrentQuarterInstant16434000000JPY
Noncurrent assetsPrior1YearInstant97102000000JPY
Noncurrent assetsCurrentQuarterInstant100645000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass